PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN
CA2241093
Phase 3 small_molecule active
Quick answer
PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN for Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active